Catherine Mazzacco - 04 Jun 2026 Form 4 Insider Report for Sight Sciences, Inc. (SGHT)

Reporting relationship: Director
Issuer ticker: SGHT
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:09:08 UTC
Prior SEC filing: 15 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/Jeremy Hayden, Attorney-in-Fact for Catherine Mazzacco

Key filing fact

Catherine Mazzacco filed Form 4 for Sight Sciences, Inc. (SGHT) on 05 Jun 2026.

Key facts

This page summarizes Catherine Mazzacco's Form 4 filing for Sight Sciences, Inc. (SGHT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 16:09.

Change

Previous filing in this sequence was filed on 15 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001967722 Primary reporting owner

Mazzacco Catherine

Relationship: Director
Address: C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK
Signature: /s/Jeremy Hayden, Attorney-in-Fact for Catherine Mazzacco
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGHT transaction

Common Stock

Award

Transaction value
Shares: +28,261
Change %: +69%
Price: $0.000000^*
Shares after: 69,276
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1, F2

SGHT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 37,492
Date: 04 Jun 2026
Ownership: See footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

Footnote F2

Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported.

Footnote F3

These shares of Common Stock are held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is beneficiary.